Charles Schwab’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-284,649
| Closed | -$453K | – | 3728 |
|
|
2024
Q1 | $453K | Buy |
284,649
+5,945
| +2% | +$9.45K | ﹤0.01% | 3063 |
|
|
2023
Q4 | $239K | Buy |
278,704
+3,640
| +1% | +$3.13K | ﹤0.01% | 3254 |
|
|
2023
Q3 | $294K | Buy |
275,064
+3,376
| +1% | +$3.61K | ﹤0.01% | 3217 |
|
|
2023
Q2 | $704K | Sell |
271,688
-53,436
| -16% | -$138K | ﹤0.01% | 2896 |
|
|
2023
Q1 | $1.33M | Sell |
325,124
-2,850
| -0.9% | -$11.6K | ﹤0.01% | 2637 |
|
|
2022
Q4 | $1.65M | Buy |
327,974
+13,415
| +4% | +$67.3K | ﹤0.01% | 2623 |
|
|
2022
Q3 | $4.12M | Buy |
314,559
+2,884
| +0.9% | +$37.7K | ﹤0.01% | 2311 |
|
|
2022
Q2 | $4M | Buy |
311,675
+12,128
| +4% | +$155K | ﹤0.01% | 2290 |
|
|
2022
Q1 | $4.57M | Buy |
299,547
+19,079
| +7% | +$291K | ﹤0.01% | 2319 |
|
|
2021
Q4 | $4.97M | Buy |
280,468
+5,222
| +2% | +$92.5K | ﹤0.01% | 2358 |
|
|
2021
Q3 | $5.79M | Buy |
275,246
+93,136
| +51% | +$1.96M | ﹤0.01% | 2301 |
|
|
2021
Q2 | $3.59M | Buy |
182,110
+18,137
| +11% | +$358K | ﹤0.01% | 2509 |
|
|
2021
Q1 | $4.77M | Buy |
163,973
+32,474
| +25% | +$944K | ﹤0.01% | 2322 |
|
|
2020
Q4 | $3.98M | Buy |
131,499
+1,839
| +1% | +$55.7K | ﹤0.01% | 2331 |
|
|
2020
Q3 | $2.06M | Buy |
129,660
+47,599
| +58% | +$757K | ﹤0.01% | 2482 |
|
|
2020
Q2 | $1.62M | Buy |
82,061
+1,354
| +2% | +$26.7K | ﹤0.01% | 2486 |
|
|
2020
Q1 | $996K | Buy |
80,707
+1,655
| +2% | +$20.4K | ﹤0.01% | 2491 |
|
|
2019
Q4 | $1.46M | Buy |
79,052
+38,591
| +95% | +$714K | ﹤0.01% | 2493 |
|
|
2019
Q3 | $561K | Buy |
40,461
+1,974
| +5% | +$27.4K | ﹤0.01% | 2756 |
|
|
2019
Q2 | $564K | Buy |
+38,487
| New | +$564K | ﹤0.01% | 2755 |
|